STAAR Surgical (NASDAQ:STAA) Receives Average Rating of "Hold" from Analysts

STAAR Surgical (NASDAQ:STAA - Get Free Report) has received a consensus rating of "Hold" from the ten brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $25.29.

STAA has been the subject of several analyst reports. Stifel Nicolaus reduced their price objective on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a report on Thursday, February 27th. Piper Sandler dropped their target price on shares of STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a report on Wednesday, February 12th. William Blair cut shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 12th. Finally, StockNews.com lowered STAAR Surgical from a "hold" rating to a "sell" rating in a research note on Thursday, February 13th.

Remove Ads

STAAR Surgical Stock Performance

STAA traded down $0.31 during trading on Friday, reaching $17.46. The company had a trading volume of 621,090 shares, compared to its average volume of 765,949. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68. The company has a market cap of $861.21 million, a price-to-earnings ratio of -42.59 and a beta of 0.66. The firm's 50-day simple moving average is $19.77 and its 200 day simple moving average is $25.52.

Insiders Place Their Bets

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 8,221 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The stock was purchased at an average price of $21.50 per share, with a total value of $176,751.50. Following the completion of the transaction, the insider now directly owns 10,878,007 shares of the company's stock, valued at approximately $233,877,150.50. This trade represents a 0.08 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders bought 1,036,187 shares of company stock worth $17,239,548. 1.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On STAAR Surgical

A number of institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in STAAR Surgical by 13.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier's stock valued at $2,684,000 after purchasing an additional 13,075 shares during the last quarter. Voloridge Investment Management LLC lifted its stake in shares of STAAR Surgical by 9.4% during the fourth quarter. Voloridge Investment Management LLC now owns 296,256 shares of the medical instruments supplier's stock valued at $7,196,000 after acquiring an additional 25,350 shares during the period. Squarepoint Ops LLC lifted its holdings in STAAR Surgical by 81.3% in the fourth quarter. Squarepoint Ops LLC now owns 117,074 shares of the medical instruments supplier's stock valued at $2,844,000 after buying an additional 52,488 shares during the period. Sherbrooke Park Advisers LLC acquired a new stake in shares of STAAR Surgical during the fourth quarter worth $502,000. Finally, Raiffeisen Bank International AG bought a new stake in shares of STAAR Surgical in the 4th quarter valued at about $1,926,000. 96.70% of the stock is owned by institutional investors and hedge funds.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.